Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Net Income
Bottom-line profit after all expenses, interest, and taxes.
Bausch Health Companies Inc.NYSE: BHC
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $258M rose 74.3% year over year, ahead of the -1220.4% change in trailing-twelve-month net income.
Context
- Net income amounted to 1.5% of revenue in FY2025, up 1.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $1.9B (+1107.8%) for the fiscal year ending Dec 2026, a step up from the +441.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $258M+118.1% QoQ
- Last fiscal yearDec 2025
- $157M+441.3% YoY
- LTMJun 2026
- -$1.1B-1220.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +74.3% | +166.3% | +92.0 pp |
| 1 year | +441.3% | +1107.8% | +666.5 pp |
| 3-year CAGR | — | +97.8% | — |
| 5-year CAGR | +49.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 157M USD
- Year-over-year change
- +441.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 157M | +441.3% |
| FY2024 | 2024-12-31 | (46M) | +92.2% |
| FY2023 | 2023-12-31 | (592M) | -163.1% |
| FY2022 | 2022-12-31 | (225M) | +76.3% |
| FY2021 | 2021-12-31 | (948M) | — |
Net Income vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 net income of -$1.1B is the 10th highest of the 11 companies compared; the peer median is $4.47M.
- Its year-over-year change of -1220.4% is the 10th highest of 11, against a peer median of +21.5%.
- Net income amounts to 10.1% of revenue for BHC, versus a peer median of 17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $466.88M | +1212.4% | — | 77.5% | |
| LTM Mar 2026 | $221.32M | +12.1% | +37.1% | 37.1% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $216.36M | +41.2% | -0.1% | 9.3% |
| LTM Jun 2026 | $96.29M | -41.1% | -5.5% | 7.1% | |
| LTM Mar 2026 | $89.67M | +526.0% | — | 9.7% | |
| LTM Mar 2026 | -$80.73M | -183.6% | — | 14.4% | |
| LTM Jun 2026 | -$85.43M | +78.6% | — | 54.7% | |
| LTM Jun 2026 | -$349.58M | -83.2% | — | — | |
| LTM Mar 2026 | -$628M | +30.8% | — | 17.1% | |
| LTM Jun 2026 | -$1.1B | -1220.4% | — | 10.1% | |
| LTM Jun 2026 | -$1.73B | -2060.3% | — | 41.9% | |
| Peer median (excluding BHC) | $4.47M | +21.5% | -0.1% | 17.1% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.43B | 8.12B | 8.76B | 9.63B | 10.27B |
| Cost of Revenue | 2.39B | 2.36B | 2.56B | 2.78B | 3.01B |
| Gross Profit | 6.04B | 5.76B | 6.2B | 6.84B | 7.25B |
| Gross Margin | 71.6% | 70.9% | 70.8% | 71.1% | 70.7% |
| Research & Development | 473M | 530M | 604M | 634M | 629M |
| Selling, General & Admin | 2.49B | 2.53B | 2.9B | 3.28B | 3.44B |
| Operating Expenses | 5.59B | 5.31B | 5.24B | 5.3B | 5.07B |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| EBITDA | 3.26B | 2.88B | 2.89B | 3.13B | 3.18B |
| EBITDA Margin | 38.7% | 35.4% | 32.9% | 32.6% | 31.0% |
| Operating Income | 450M | 454M | 963M | 1.55B | 2.19B |
| Operating Margin | 5.3% | 5.6% | 11.0% | 16.1% | 21.3% |
| Interest Income | 7M | 14M | 26M | 33M | 48M |
| Interest Expense | 1.43B | 1.46B | 1.33B | 1.39B | 1.6B |
| Other Income / Expenses | (1.47B) | (583M) | (1.35B) | (1.38B) | (1.82B) |
| Income Before Tax | (1.02B) | (129M) | (390M) | 167M | 367M |
| Pre-Tax Margin | -12.1% | -1.6% | -4.5% | 1.7% | 3.6% |
| Income Tax Expense | (87M) | 83M | 221M | 239M | 247M |
| Net Income | (948M) | (225M) | (592M) | (46M) | 157M |
| Net Margin | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| EPS (Basic) | (2.61) | (0.62) | (1.62) | (0.13) | 0.43 |
| EPS (Diluted) | (2.61) | (0.62) | (1.62) | (0.13) | 0.43 |
| Weighted Avg Shares | 358.9M | 362M | 364.9M | 368M | 370.9M |
| Weighted Avg Shares (Diluted) | 358.9M | 362M | 364.9M | 368M | 375M |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.